EarningsQ2 2026 Earnings Report
DE:4E2 Q2 2026 EPS Results
Actual EPS-€0.10
Consensus EPS-€0.17
Beat/MissBeat by +€0.08
One Year Ago EPS-€0.26
DE:4E2 Q2 2026 Revenue Results
Actual Revenue€0.00
Expected Revenue€0.00
Beat/MissMet expectations
YoY Revenue Growth―
Earnings Announcement Details
QuarterQ2 2026
Date08/06/2026
TimeAfter Close
Conference CallThursday, August 6, 2026
DE:4E2 Upcoming Earnings
Relmada Therapeutics's next earnings date is estimated for November 5, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
DE:4E2 Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
Overall the call conveyed a constructive and execution-focused tone: Relmada reported a materially strengthened balance sheet (cash +134% YoY) with a cash runway into 2029, compelling 12-month Phase II efficacy and favorable safety for NDV-01, clear FDA-aligned registration pathways, an experienced new CBO, and engaged clinical sites. Key near-term risks center on manufacturing/CMC execution (GMP batch production and stability data), which shifted IND timing toward year-end 2026 and has increased R&D spend and operating cash use. On balance the company appears well-capitalized and positioned to advance registrational programs, but outcomes hinge on resolving manufacturing scale-up and timing.Company Guidance
Strong Cash Position and Runway
Cash, cash equivalents and short-term investments of $217.7M at 6/30/2026 vs $93.0M at 12/31/2025 (increase of ~134%), with management stating current resources are expected to fund operations through 2029, including completion of the Phase III RESCUE program for NDV-01.
Compelling Phase II Clinical Data for NDV-01
12-month Phase II results: 95% of patients achieved a complete response at any time and 76% had a durable complete response at 12 months; safety profile described as favorable.
Regulatory Alignment and Clear Development Path
Company reports FDA alignment on two planned registration pathways for NDV-01 and plans to file the NDV-01 IND by year-end 2026 and initiate the Phase III RESCUE registrational program upon IND clearance.
Sepranolone Program Near IND
Sepranolone formulation development complete for Prader-Willi Syndrome; plan to file sepranolone IND by year-end 2026 and initiate a Phase II proof-of-concept study upon IND clearance.
Experienced Leadership Strengthened
Appointment of Bipin Dalmia as Chief Business Officer, bringing ~3 decades of uro-oncology and commercialization experience, including prior launch experience in intravesical gene therapy; management emphasizes strengthened leadership and execution capability.
Clinical Readiness and Site Network
Management reports approximately 80 clinical sites engaged (~60 primary, ~20 backup) and states sites are prepared to begin enrolling patients as soon as IND is cleared and clinical material is available.
Improved G&A Expense Management
General and administrative expense decreased to $6.6M for the quarter vs $7.4M year-over-year (decrease of ~$0.8M, ~10.8%), driven by lower stock-based compensation and employee compensation.
EPS Improvement Despite Higher Net Loss
Net loss for the quarter was $12.9M, or $0.11 per basic and diluted share, compared with a net loss of $9.9M, or $0.30 per share in Q2 2025 — per-share loss improved materially even as absolute net loss increased.
DE:4E2 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed